Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry.

Autor: Larsen CP; Department of Surgery, Emory University Transplant Center, Atlanta, GA., Vincenti F; Departments of Medicine and Surgery, University of California, San Francisco, Transplant Center, San Francisco, CA., D Kou T; Worldwide Patient Safety, Bristol Myers Squibb, Princeton, NJ., Shadur CA; Transplantation Service, Iowa Kidney Physicians, Des Moines, IA., Bresnahan B; Division of Nephrology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Jordan SC; Comprehensive Transplant Center, Cedars Sinai, Los Angeles, CA., Woodle ES; Department of Surgery, University of Cincinnati, Cincinnati, OH., Goes N; Kidney Transplant Clinics, Kaiser Permanente, San Francisco, CA., Vella J; Division of Nephrology and Transplantation, Maine Nephrology Associates, Portland, ME., Wojciechowski D; Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX., Polinsky MS; Research and Development/Global Drug Development, Bristol Myers Squibb, Princeton, NJ., Gomez-Caminero A; Worldwide Health Economic and Outcomes Research, Bristol Myers Squibb, Princeton, NJ.

Publikováno v: Transplantation direct [Transplant Direct] 2024 May 17; Vol. 10 (6), pp. e1644. Date of Electronic Publication: 2024 May 17 (Print Publication: 2024).